Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Deng J, Li J, Sarde A, Lines JL, Lee YC, Qian DC, Pechenick DA, Manivanh R, Le Mercier I, Lowrey CH, Varn FS, Cheng C, Leib DA, Noelle RJ, Mabaera R.

Cancer Immunol Res. 2019 Jul;7(7):1079-1090. doi: 10.1158/2326-6066.CIR-18-0507. Epub 2019 May 14.

PMID:
31088847
2.

Pollen/Fruit Syndrome: Clinical Relevance of the Cypress Pollen Allergenic Gibberellin-Regulated Protein.

Sénéchal H, Keykhosravi S, Couderc R, Selva MA, Shahali Y, Aizawa T, Busnel JM, Arif R, Mercier I, Pham-Thi N, Charpin DA, Poncet P.

Allergy Asthma Immunol Res. 2019 Jan;11(1):143-151. doi: 10.4168/aair.2019.11.1.143.

3.

CAPER as a therapeutic target for triple negative breast cancer.

Campbell MC, Pontiggia L, Russell AY, Schwarting R, Camacho J, Jasmin JF, Mercier I.

Oncotarget. 2018 Jul 13;9(54):30340-30354. doi: 10.18632/oncotarget.25719. eCollection 2018 Jul 13.

4.

The C-Type Lectin Receptor DC-SIGN Has an Anti-Inflammatory Role in Human M(IL-4) Macrophages in Response to Mycobacterium tuberculosis.

Lugo-Villarino G, Troegeler A, Balboa L, Lastrucci C, Duval C, Mercier I, Bénard A, Capilla F, Al Saati T, Poincloux R, Kondova I, Verreck FAW, Cougoule C, Maridonneau-Parini I, Sasiain MDC, Neyrolles O.

Front Immunol. 2018 Jun 12;9:1123. doi: 10.3389/fimmu.2018.01123. eCollection 2018.

5.

B Cells Producing Type I IFN Modulate Macrophage Polarization in Tuberculosis.

Bénard A, Sakwa I, Schierloh P, Colom A, Mercier I, Tailleux L, Jouneau L, Boudinot P, Al-Saati T, Lang R, Rehwinkel J, Loxton AG, Kaufmann SHE, Anton-Leberre V, O'Garra A, Sasiain MDC, Gicquel B, Fillatreau S, Neyrolles O, Hudrisier D.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):801-813. doi: 10.1164/rccm.201707-1475OC.

6.

Immunoregulatory functions of VISTA.

Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, Kuta A, Le Mercier I, Cheng C, Noelle RJ.

Immunol Rev. 2017 Mar;276(1):66-79. doi: 10.1111/imr.12525. Review.

7.

C-type lectin receptor DCIR modulates immunity to tuberculosis by sustaining type I interferon signaling in dendritic cells.

Troegeler A, Mercier I, Cougoule C, Pietretti D, Colom A, Duval C, Vu Manh TP, Capilla F, Poincloux R, Pingris K, Nigou J, Rademann J, Dalod M, Verreck FA, Al Saati T, Lugo-Villarino G, Lepenies B, Hudrisier D, Neyrolles O.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E540-E549. doi: 10.1073/pnas.1613254114. Epub 2017 Jan 9.

8.

A New VISTA on combination therapy for negative checkpoint regulator blockade.

Deng J, Le Mercier I, Kuta A, Noelle RJ.

J Immunother Cancer. 2016 Dec 20;4:86. doi: 10.1186/s40425-016-0190-5. eCollection 2016. Review.

9.

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.

Le Mercier I, Lines JL, Noelle RJ.

Front Immunol. 2015 Aug 21;6:418. doi: 10.3389/fimmu.2015.00418. eCollection 2015. Review.

10.

Collectin CL-LK Is a Novel Soluble Pattern Recognition Receptor for Mycobacterium tuberculosis.

Troegeler A, Lugo-Villarino G, Hansen S, Rasolofo V, Henriksen ML, Mori K, Ohtani K, Duval C, Mercier I, Bénard A, Nigou J, Hudrisier D, Wakamiya N, Neyrolles O.

PLoS One. 2015 Jul 14;10(7):e0132692. doi: 10.1371/journal.pone.0132692. eCollection 2015.

11.

Predicting pathogen-specific CD8 T cell immune responses from a modeling approach.

Crauste F, Terry E, Mercier IL, Mafille J, Djebali S, Andrieu T, Mercier B, Kaneko G, Arpin C, Marvel J, Gandrillon O.

J Theor Biol. 2015 Jun 7;374:66-82. doi: 10.1016/j.jtbi.2015.03.033. Epub 2015 Apr 3.

12.

Studying mast cells in peripheral tolerance by using a skin transplantation model.

de Vries VC, Le Mercier I, Nowak EC, Noelle RJ.

Methods Mol Biol. 2015;1220:461-86. doi: 10.1007/978-1-4939-1568-2_28.

PMID:
25388268
13.

Caveolin-1 regulates the anti-atherogenic properties of macrophages.

Pavlides S, Gutierrez-Pajares JL, Katiyar S, Jasmin JF, Mercier I, Walters R, Pavlides C, Pestell RG, Lisanti MP, Frank PG.

Cell Tissue Res. 2014 Dec;358(3):821-31. doi: 10.1007/s00441-014-2008-4. Epub 2014 Oct 17.

PMID:
25322709
14.

Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.

Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, Nowak EC, Suriawinata AA, Li J, Noelle RJ.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14846-51. doi: 10.1073/pnas.1407447111. Epub 2014 Sep 29.

15.

VISTA Regulates the Development of Protective Antitumor Immunity.

Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L.

Cancer Res. 2014 Apr 1;74(7):1933-44. doi: 10.1158/0008-5472.CAN-13-1506.

16.

CAPER, a novel regulator of human breast cancer progression.

Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, Hulit J, Gandara R, Wang C, Pestell RG, Lisanti MP, Jasmin JF.

Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.

17.

Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development.

Danilo C, Gutierrez-Pajares JL, Mainieri MA, Mercier I, Lisanti MP, Frank PG.

Breast Cancer Res. 2013;15(5):R87.

18.

Multiple deletions in the polyketide synthase gene repertoire of Mycobacterium tuberculosis reveal functional overlap of cell envelope lipids in host-pathogen interactions.

Passemar C, Arbués A, Malaga W, Mercier I, Moreau F, Lepourry L, Neyrolles O, Guilhot C, Astarie-Dequeker C.

Cell Microbiol. 2014 Feb;16(2):195-213. doi: 10.1111/cmi.12214. Epub 2013 Oct 16.

PMID:
24028583
19.

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.

Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N.

Cancer Res. 2013 Aug 1;73(15):4629-40. doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.

20.

Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.

Quann K, Gonzales DM, Mercier I, Wang C, Sotgia F, Pestell RG, Lisanti MP, Jasmin JF.

Cell Cycle. 2013 May 15;12(10):1510-20. doi: 10.4161/cc.24497. Epub 2013 Apr 17.

21.

Tryptophan hydroxylase-1 regulates immune tolerance and inflammation.

Nowak EC, de Vries VC, Wasiuk A, Ahonen C, Bennett KA, Le Mercier I, Ha DG, Noelle RJ.

J Exp Med. 2012 Oct 22;209(11):2127-35. doi: 10.1084/jem.20120408. Epub 2012 Sep 24.

22.

Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.

23.

Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.

Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV, Lisanti MP.

Am J Pathol. 2012 Jul;181(1):278-93. doi: 10.1016/j.ajpath.2012.03.017. Epub 2012 Jun 13.

24.

Deciphering the genomic structure, function and evolution of carotenogenesis related phytoene synthases in grasses.

Dibari B, Murat F, Chosson A, Gautier V, Poncet C, Lecomte P, Mercier I, Bergès H, Pont C, Blanco A, Salse J.

BMC Genomics. 2012 Jun 6;13:221. doi: 10.1186/1471-2164-13-221.

25.

Caveolin-1 and breast cancer: a new clinical perspective.

Mercier I, Lisanti MP.

Adv Exp Med Biol. 2012;729:83-94. doi: 10.1007/978-1-4614-1222-9_6. Review.

PMID:
22411315
26.

Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis.

Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP.

Antioxid Redox Signal. 2012 Jun 1;16(11):1264-84. doi: 10.1089/ars.2011.4243. Epub 2011 Nov 17. Review.

27.

Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate.

Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC, Fortina P, Balasubramaniam S, Knudsen KE, Schwarting R, Lisanti MP, Mercier I.

Int J Biochem Cell Biol. 2011 Sep;43(9):1318-29. doi: 10.1016/j.biocel.2011.04.019. Epub 2011 May 12.

PMID:
21601007
28.

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, Elzi L, Rauch A, Bernasconi E, Schmid P, Hirschel B.

AIDS. 2011 Jul 31;25(12):1481-7. doi: 10.1097/QAD.0b013e328348dab0.

PMID:
21593661
29.

Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction.

Jasmin JF, Rengo G, Lymperopoulos A, Gupta R, Eaton GJ, Quann K, Gonzales DM, Mercier I, Koch WJ, Lisanti MP.

Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1274-81. doi: 10.1152/ajpheart.01173.2010. Epub 2011 Feb 4.

30.

Role of cholesterol in the development and progression of breast cancer.

Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG.

Am J Pathol. 2011 Jan;178(1):402-12. doi: 10.1016/j.ajpath.2010.11.005. Epub 2010 Dec 23.

31.

A randomized crossover study to compare efavirenz and etravirine treatment.

Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L, Genné D, Rauch A, Bernasconi E, Hirschel B; Swiss HIV Cohort Study.

AIDS. 2011 Jan 2;25(1):57-63. doi: 10.1097/QAD.0b013e32833f9f63. Erratum in: AIDS. 2011 Mar 13;25(5):729. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
21076278
32.

The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.

Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP.

Cell Cycle. 2010 Nov 1;9(21):4297-306. Epub 2010 Nov 30. Review.

33.

Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy.

Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, Jasmin JF, Frank PG, Pestell RG, Kleer CG, Sotgia F, Lisanti MP.

Cell Cycle. 2009 Jun 1;8(11):1654-8.

PMID:
19448435
34.

An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.

Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP.

Am J Pathol. 2009 Jun;174(6):2023-34. doi: 10.2353/ajpath.2009.080873. Epub 2009 May 1.

35.

Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.

Bonuccelli G, Casimiro MC, Sotgia F, Wang C, Liu M, Katiyar S, Zhou J, Dew E, Capozza F, Daumer KM, Minetti C, Milliman JN, Alpy F, Rio MC, Tomasetto C, Mercier I, Flomenberg N, Frank PG, Pestell RG, Lisanti MP.

Am J Pathol. 2009 May;174(5):1650-62. doi: 10.2353/ajpath.2009.080648.

36.

Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation.

Mercier I, Bryant KG, Sotgia F, Bonuccelli G, Witkiewicz AK, Dasgupta A, Jasmin JF, Pestell RG, Lisanti MP.

Cell Cycle. 2009 May 1;8(9):1396-401. Epub 2009 May 26.

PMID:
19342880
37.

Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions.

Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Apr;174(4):1172-90. doi: 10.2353/ajpath.2009.080882.

38.

Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders.

Mercier I, Jasmin JF, Pavlides S, Minetti C, Flomenberg N, Pestell RG, Frank PG, Sotgia F, Lisanti MP.

Lab Invest. 2009 Jun;89(6):614-23. doi: 10.1038/labinvest.2009.23. Epub 2009 Mar 30. Review.

39.

Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.

Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, Minetti C, Frank PG, Jimenez SA, Knudsen ES, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Mar;174(3):746-61. doi: 10.2353/ajpath.2009.080658.

40.

Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.

Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang C, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Feb;174(2):613-29. doi: 10.2353/ajpath.2009.080653.

41.

ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.

Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN.

Cell Cycle. 2008 Jun 1;7(11):1640-7. Epub 2008 Mar 19.

PMID:
18469522
42.

Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.

Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP.

Cancer Biol Ther. 2008 Aug;7(8):1212-25. Epub 2008 Aug 30.

43.

Inter-laboratory reproducibility of the LC-ELSD method for the control of composition of sesame oil recently introduced in the Ph. Eur.

Lodi A, Mercier I, Prilleux B, Streissel P, Thietard L.

Pharmeur Sci Notes. 2007 Sep;2007(1):39-41.

PMID:
17993093
44.

Caveolin-1 deficiency increases cerebral ischemic injury.

Jasmin JF, Malhotra S, Singh Dhallu M, Mercier I, Rosenbaum DM, Lisanti MP.

Circ Res. 2007 Mar 16;100(5):721-9. Epub 2007 Feb 9.

PMID:
17293479
45.

Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers.

Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP.

Cancer Res. 2006 Nov 15;66(22):10647-51. Review.

46.

Interleukin-17 is a negative regulator of established allergic asthma.

Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez F, Ryffel B, Schnyder B.

J Exp Med. 2006 Nov 27;203(12):2715-25. Epub 2006 Nov 13.

47.

Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.

Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, Lisanti MP.

Am J Pathol. 2006 Nov;169(5):1784-801.

48.
49.

SOCS proteins and caveolin-1 as negative regulators of endocrine signaling.

Jasmin JF, Mercier I, Sotgia F, Lisanti MP.

Trends Endocrinol Metab. 2006 May-Jun;17(4):150-8. Epub 2006 Apr 17. Review.

PMID:
16616514
50.

Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.

Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I.

Cancer Immunol Immunother. 2006 Mar;55(3):254-67. Epub 2005 Aug 27.

PMID:
16133115

Supplemental Content

Loading ...
Support Center